Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985;20(Suppl 1):29S–49S. doi: 10.1111/j.1365-2125.1985.tb05142.x

Nicardipine in models of myocardial infarction

B J Alps, C Calder, A Wilson
PMCID: PMC1400792  PMID: 4027150

Abstract

1 In a dog model of partial myocardial ischaemia, superimposed ST segment elevations in epicardial ECGs were inhibited by nicardipine over a cumulative i.v. dose range of 1-20 μg kg-1.

2 Over the cumulative i.v. dose range of 0.5-166.5 μg kg-1, nicardipine had little overall effect on gross cardiac conduction, at spontaneous heart rate.

3 Dogs that received oral 1-2 mg kg-1 nicardipine daily for 16 weeks and then survived 1 week occlusion of the left anterior descending coronary artery (LAD) developed a superior coronary collateral circulation compared with untreated animals.

4 Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion.

5 Compared with a group of completely untreated dogs, there was protection of the myocardium in the animals given nicardipine that survived 3 months occlusion of the LAD.

Keywords: myocardial infarct, animal models, nicardipine, pharmacology

Full text

PDF

Images in this article

38SFigure 7
on p.38S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alps B. J., Calder C., Wilson A., Scott-Park F. M. The beneficial effect of nicardipine on the healing of myocardial infarcts in dogs. Arzneimittelforschung. 1983;33(12):1638–1646. [PubMed] [Google Scholar]
  2. Alps B. J., Calder C., Wilson A. The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons. Arzneimittelforschung. 1983;33(6):868–876. [PubMed] [Google Scholar]
  3. Barker B., Rosario M. D., Grant V., McNamara J. J., Suehiro G. T. Infarct distribution in subhuman primates after acute coronary occlusion. Cardiovasc Res. 1980 Dec;14(11):671–674. doi: 10.1093/cvr/14.11.671. [DOI] [PubMed] [Google Scholar]
  4. Baum T., Rowles G., Shropshire A. T. Antiarrhythmic actions of two new beta adrenergic blocking agents, Kö 1313 and Kö 1366. J Pharmacol Exp Ther. 1971 Feb;176(2):350–360. [PubMed] [Google Scholar]
  5. Chambers D. E., Yellon D. M., Hearse D. J., Downey J. M. Effects of flurbiprofen in altering the size of myocardial infarcts in dogs: reduction or delay? Am J Cardiol. 1983 Mar 1;51(5):884–890. doi: 10.1016/s0002-9149(83)80149-0. [DOI] [PubMed] [Google Scholar]
  6. Csik V., Szekeres L., Udvary E. Comparison of two calcium antagonists, verapamil and fendiline, in an experimental model of myocardial ischaemia mimicking classical angina on effort. Br J Pharmacol. 1983 May;79(1):37–43. doi: 10.1111/j.1476-5381.1983.tb10492.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fishbein M. C., Meerbaum S., Rit J., Lando U., Kanmatsuse K., Mercier J. C., Corday E., Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 1981 May;101(5):593–600. doi: 10.1016/0002-8703(81)90226-x. [DOI] [PubMed] [Google Scholar]
  8. Geary G. G., Smith G. T., Suehiro G. T., McNamara J. J. Failure of nifedipine therapy to reduce myocardial infarct size in the baboon. Am J Cardiol. 1982 Feb 1;49(2):331–338. doi: 10.1016/0002-9149(82)90509-4. [DOI] [PubMed] [Google Scholar]
  9. Grinwald P. M., Nayler W. G. Calcium entry in the calcium paradox. J Mol Cell Cardiol. 1981 Oct;13(10):867–880. doi: 10.1016/0022-2828(81)90286-8. [DOI] [PubMed] [Google Scholar]
  10. Hearse D. J., Yellon D. M. The "border zone" in evolving myocardial infarction: controversy or confusion? Am J Cardiol. 1981 Jun;47(6):1321–1334. doi: 10.1016/0002-9149(81)90266-6. [DOI] [PubMed] [Google Scholar]
  11. Henry P. D., Schuchleib R., Davis J., Weiss E. S., Sobel B. E. Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol. 1977 Dec;233(6):H677–H684. doi: 10.1152/ajpheart.1977.233.6.H677. [DOI] [PubMed] [Google Scholar]
  12. Henry P. D., Shuchleib R., Borda L. J., Roberts R., Williamson J. R., Sobel B. E. Effects of nifedipine on myocardial perfusion and ischemic injury in dogs. Circ Res. 1978 Sep;43(3):372–380. doi: 10.1161/01.res.43.3.372. [DOI] [PubMed] [Google Scholar]
  13. Higuchi S., Sasaki H., Shiobara Y., Sado T. Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. Xenobiotica. 1977 Aug;7(8):469–479. doi: 10.3109/00498257709035806. [DOI] [PubMed] [Google Scholar]
  14. Hillis L. D., Askenazi J., Braunwald E., Radvany P., Muller J. E., Fishbein M. C., Maroko P. R. Use of changes in the epicardial QRS complex to assess interventions which modify the extent of myocardial necrosis following coronary artery occlusion. Circulation. 1976 Oct;54(4):591–598. doi: 10.1161/01.cir.54.4.591. [DOI] [PubMed] [Google Scholar]
  15. Lubbe W. F., Peisach M., Pretorius R., Bruyneel K. J., Opie L. H. Distribution of myocardial blood flow before and after coronary artery ligation in the baboon. Relation to early ventricular fibrillation. Cardiovasc Res. 1974 Jul;8(4):478–487. doi: 10.1093/cvr/8.4.478. [DOI] [PubMed] [Google Scholar]
  16. MEESMANN W., BUSCH G., BRAASCH W., BACHMANN G. W. ENTWICKLUNG VON KORONAR-KOLLATERALEN DURCH CHRONISCHE ORALE PERSANTIN -BEHANDLUNG. Med Welt. 1964 May 16;20:1106–1111. [PubMed] [Google Scholar]
  17. Maroko P. R., Deboer L. W., Davis R. F. Infarct size reduction: A critical review. Adv Cardiol. 1980;27:127–169. doi: 10.1159/000383982. [DOI] [PubMed] [Google Scholar]
  18. Meesmann W., Bachmann G. W. Pharmakodynamisch induzierte Entwicklung von Koronar-Kollateralen in Abhängigkeit von der Dosis. Arzneimittelforschung. 1966 Apr;16(4):501–509. [PubMed] [Google Scholar]
  19. Nakaya H., Kanno M. Effects of nicardipine, a new dihydropyridine vasodilator, on coronary circulation and ischemia-induced conduction delay in dogs. Arzneimittelforschung. 1982;32(6):626–629. [PubMed] [Google Scholar]
  20. Nayler W. G. Calcium antagonists. Eur Heart J. 1980 Jun;1(3):225–237. doi: 10.1093/oxfordjournals.eurheartj.a061123. [DOI] [PubMed] [Google Scholar]
  21. Reid D. S., Pelides L. J., Shillingford J. P. Surface mapping of RS-T segment in acute myocardial infarction. Br Heart J. 1971 May;33(3):370–374. doi: 10.1136/hrt.33.3.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reimer K. A., Lowe J. E., Jennings R. B. Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation. 1977 Apr;55(4):581–587. doi: 10.1161/01.cir.55.4.581. [DOI] [PubMed] [Google Scholar]
  23. Schaper W. K., Xhonneux R., Jageneau A. H. Stimulation of the coronary collateral circulation by lidoflazine (R 7904). Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965 Nov 4;252(1):1–8. doi: 10.1007/BF00246424. [DOI] [PubMed] [Google Scholar]
  24. Schuster E. H., Bulkley B. H. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation. 1979 Dec;60(7):1532–1538. doi: 10.1161/01.cir.60.7.1532. [DOI] [PubMed] [Google Scholar]
  25. Smith H. J., Singh B. N., Nisbet H. D., Norris R. M. Effects of verapamil on infarct size following experimental coronary occlusion. Cardiovasc Res. 1975 Jul;9(4):569–578. doi: 10.1093/cvr/9.4.569. [DOI] [PubMed] [Google Scholar]
  26. Szekeres L., Csik V., Udvary E. Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. J Pharmacol Exp Ther. 1976 Jan;196(1):15–28. [PubMed] [Google Scholar]
  27. Takenaka T., Usuda S., Nomura T., Maeno H., Sado T. Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93). Arzneimittelforschung. 1976;26(12):2172–2178. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES